Antibodies against cancer antigen TMEFF2 and uses thereof
Details for Australian Patent Application No. 2003252830 (hide)
International Classifications
Event Publications
23 October 2003 Complete Application Filed
Priority application(s): 60/436,812 27.12.02 US; 60/362,837 08.03.02 US
30 October 2003 Application Open to Public Inspection
Published as AU-B-2003252830
20 July 2006 Change of Name(s) of Applicant(s), Section 104
Protein Design Labs, Inc. The name of the applicant has been changed to PDL BioPharma, Inc.
9 October 2008 Application Accepted
Published as AU-B-2003252830
5 February 2009 Standard Patent Sealed
23 July 2009 Assignment Registered
PDL BioPharma, Inc. The patent has been assigned to Facet Biotech Corporation
3 February 2011 Alteration of Name
The name of the patentee has been altered to Abbott Biotherapeutics Corp. 2004
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2003252829-METHOD AND ARRANGEMENT FOR UTILITY POLE REINFORCEMENT
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser